Allergan has received US Food and Drug Administration (FDA) approval for OZURDEX (dexamethasone intravitreal implant) 0.7mg, as the first drug therapy for the treatment of macular edema.

OZURDEX is a first-of-its kind therapy administered via intravitreal injection delivering dexamethasone, a highly potent corticosteroid, via Allergan’s proprietary and innovative NOVADUR solid polymer delivery system.

Allergan vice-president of R&D and chief scientific officer Scott Whitcup said that OZURDEX is the first injectable, sustained-release, potent steroid implant that provides prolonged efficacy and a favourable safety profile.

“In clinical studies, 20–30% of patients suffering from this severe retinal condition experienced a three-line improvement in best-corrected visual acuity with an onset of effect within the first two months following therapy,” said Whitcup.

OZURDEX is a treatment for macular edema following branch retinal vein occlusion or central retinal vein occlusion.